Description
Members of the caspase family play key roles in inflammation and mammalian apoptosis. Z-LEHD-FMK is an irreversible and cell permeable inhibitor of caspase-9. The peptide is O-methylated in the P1 position on aspartic acid providing enhanced stability and increased cell permeability. Z-LEHD-FMK can be used to inhibit primarily caspase-9 activity and to study events downsteam of caspase-9 activation. Z-LEHD-FMK has been reported to have a molecular weight of 804 Daltons.
Format
- FormatPurified
Suggested Companion Products
PE Annexin V Apoptosis Detection Kit I RUO Cat No: 559763
Z-FA-FMK, Negative Control for Caspase Inhibitors RUO 1mgCat No: 550411
| Resources & Tools | ||||||
|---|---|---|---|---|---|---|
| SpectrumViewer | Download TDS | Regulatory Document Website | ||||
Preparation and Storage
Avoid multiple freeze-thaws of product.Z-LEHD-FMK, Caspase-9 Inhibitor is provided as a lyophilized powder.Store the lyophilized inhibitor at -20˚C. Reconstitute the inhibitor in DMSO before use. The reconstituted inhibitor may be stored in small aliquots at -20˚C.
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
The Z-LEHD-FMK inhibitor can be used for both in vivo and in vitro cell based assays to measure the inhibition of apoptosis. While there are numerous methods to induce and measure apoptosis, Annexin V staining can be used on Jurkat cells (Human T-cell leukemia; ATCC TIB-152) for evaluating apoptosis (see figure).
Reconstitute 1.0 mg of Z-LEHD-FMK in DMSO. A 10 mM stock solution may be prepared by dissolving 1.0 mg of Z-LEHD-FMK in 124 µl DMSO. When using the Z-LEHD-FMK inhibitor, the optimal concentration needed may vary with the experimental system being used and investigators are highly encouraged to titrate the reagent. As a precautionary note, please do not exceed a final DMSO concentration of 0.2% as higher levels may increase the risk for cellular toxicity which may mask the effect of the caspase inhibitor.
